Aiforia signs an agreement with a prestigious cancer institute in the United States
Aiforia Technologies Plc, Press Release, December 30, 2025, at 12:00 pm EET
Aiforia has signed an agreement with a world-renowned cancer institute in the United States to collaborate on AI-powered image analysis. The Collaboration includes the use of Aiforia’s AI training tool, Aiforia® Create, specifically to develop AI models for spatial Biology applications. The agreement is signed for two years.
“This Collaboration with a globally recognized cancer institute is a significant validation of Aiforia’s platform and its potential to accelerate advanced research. We are excited to support their work in developing cutting-edge AI models which hold the potential to advance cancer research,” says Jukka Tapaninen, CEO of Aiforia.
Aiforia® Create is the most versatile AI model development platform for digital pathology. Built specifically for pathologists and scientists, the platform empowers groundbreaking discoveries from image data and unlocks new opportunities through quantitative insights. Continuously evolving, Aiforia® Create now supports advanced functionalities, including the use of foundation models in AI training – making it the most flexible and future-ready tool for AI model training in pathology.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a Trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on Pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com
SOURCE: Kauppalehti
